CHANGE IN RATINGS

AmerisourceBergen ( ABC) upgraded at Deutsche to Buy. $41.50 price target. Company has the cleanest fundamentals in the business. Expect little industry reform risk.

DryShips ( DRYS) upgraded at Oppenheimer from Perform to Outperform. $8 price target. See little further dilution after the latest offering.

Fidelity National ( FIS) upgraded at Oppenheimer. Rating raised to Outperform from Perform. Establishes price target of $25. Maintains 2009 EPS estimates of $1.61.

Illinois Tool Works ( ITW) downgraded at BB&T from Buy to Hold. Valuation call, as sales are weak but stable.

Palm ( PALM) downgraded at Morgan Joseph from Buy to Hold. Valuation call, with the stock reaching the $10 price target.

Quality Systems ( QSII) downgraded at BB&T to Hold. Valuation call, as the stock is up 79% since December 3.

STOCK COMMENTS / EPS CHANGES

Advanced Micro Devices ( AMD) estimates lowered at UBS. AMD loss estimates widened through 2010. Company seeing higher sales on improved PC trends, but is realizing higher loss from the Globalfoundries subsidiary. Neutral rating and $2.20 price target.

Baxter ( BAX) estimates raised at UBS through 2010. Bioscience division continues to be the main growth driver. Buy rating and $60 price target.

Bed, Bath & Beyond ( BBBY) numbers upped at Barclays to $27. Estimates also increased, following an upbeat meeting with management. Equal-weight rating.

Biogen Idec ( BIIB) estimates, target raised at Barclays to $40. Estimates also raised to reflect lower tax rates. Underweight rating.

Crown Holdings ( CCK) numbers raised at UBS to $29. Estimates also increased, because of improved operating efficiency. Buy rating.

Cypress Semi ( CY) estimates lowered at UBS through 2010. Company realizing better sales, but is facing higher stock compensation costs. Neutral rating and $7 price target.

Cypress Semi ( CY) numbers increased at Barclays to $9. Estimates also raised, to reflect higher sales demand. Overweight rating.

Google ( GOOG) estimates raised at Barclays through 2010, Barclays Capital said. Company is seeing leverage on cost controls. Overweight rating and $460 price target.

Intuitive Surgical ( ISRG) estimates raised at Morgan Stanley through 2010. Company posted a strong quarter, and the buyback program helped to boost earnings. Equal-weight rating.

Nokia ( NOK) estimates, target raised at Barclays through 2010. Company is selling more handsets and visibility is improving. Overweight rating and new $17 price target.

Parker Hannifin ( PH) estimates reduced at UBS through 2010. Demand remains weak, with little visibility for a turnaround. Neutral rating and $39 price target.

Sprint Nextel ( S) estimates upped at Morgan Stanley through 2011. Company is seeing growth in pre-paid subscribers, though contract customers continue to fall. Underweight rating and $1 price target.

Sandisk ( SNDK) estimates raised at UBS; loss estimates improved. Company realizing higher average selling prices. Neutral rating and $11.50 price target.

Textron ( TXT) target raised at Merrill/BofA to $12.50. Stock continues to trade with buyout rumors. Neutral rating.
This article was written by a staff member of TheStreet.com.

If you liked this article you might like

Why a Walgreens Purchase of Humana or WellCare Now Appears Less Likely

Why a Walgreens Purchase of Humana or WellCare Now Appears Less Likely

Does Walgreens Buying AmerisourceBergen Make Any Sense?

Does Walgreens Buying AmerisourceBergen Make Any Sense?

Watch: Jim Cramer Reacts to a Potential Walgreens AmerisourceBergen Deal

Watch: Jim Cramer Reacts to a Potential Walgreens AmerisourceBergen Deal

Dow Futures Are Plunging Again

Dow Futures Are Plunging Again